Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph early_phase_1
1
50%
Ph phase_1
1
50%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Early Phase 1First-in-human
1(50.0%)
Phase 1Safety & dosage
1(50.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
N/A
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 11 (50.0%)
Phase 11 (50.0%)

Trials by Status

not_yet_recruiting2100%

Recent Activity

0 active trials
Showing 2 of 2
not_yet_recruitingearly_phase_1

Allogeneic Gammadelta T Cells Combined With Interferon-α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma

NCT06212388
not_yet_recruitingphase_1

Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma

NCT05539118

Clinical Trials (2)

Showing 2 of 2 trials
NCT06212388Early Phase 1

Allogeneic Gammadelta T Cells Combined With Interferon-α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma

Not Yet Recruiting
NCT05539118Phase 1

Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma

Not Yet Recruiting

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2